A European Medicines Agency (EMA) committee recommended that the label for Kaftrio be expanded to cover treatment for people…
Articles by Marisa Wexler, MS
Boehringer Ingelheim has launched a Phase 1/2 clinical trial of BI 3720931, an inhaled gene therapy designed to treat…
Young children with cystic fibrosis (CF) have less mature gut bacterial growth over time than do their typically developing…
In cystic fibrosis (CF), certain immune cells show signs of dysfunction very early in life, according to a new…
Registration is now open for BreatheCon 2025, an annual online event hosted by the Cystic Fibrosis Foundation that…
A new triple-combination CFTR modulator therapy — vanzacaftor, tezacaftor, and deutivacaftor — has been approved by the U.S. Food and…
Infection with an airway bacterium called Haemophilus influenzae isn’t linked with worse lung health outcomes among adults with cystic…
A young man with cystic fibrosis (CF) successfully underwent a heart transplant, according to a first-of-its kind report described…
The Cystic Fibrosis Foundation is investing up to $15 million in Recode Therapeutics to help spur the development…
A Phase 1/2 clinical trial testing the inhaled gene therapy SP-101 in adults with cystic fibrosis (CF) has begun…